Jpmorgan Chase & CO Ice Cure Medical Ltd. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Ice Cure Medical Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,950 shares of ICCM stock, worth $5,057. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,950
Previous 5,950
-0.0%
Holding current value
$5,057
Previous $7,000
42.86%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ICCM
# of Institutions
16Shares Held
364KCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il170KShares$144,0850.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny66.4KShares$56,4400.0% of portfolio
-
Virtu Financial LLC New York, NY27.2KShares$23,1100.0% of portfolio
-
Geode Capital Management, LLC Boston, MA25.6KShares$21,7260.0% of portfolio
-
Two Sigma Investments, LP New York, NY21.3KShares$18,0660.0% of portfolio
About IceCure Medical Ltd.
- Ticker ICCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 36,835,600
- Market Cap $31.3M
- Description
- IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.